What is the 13F Pro Quality Score for CRNX?

13F Pro ranks Crinetics Pharmaceuticals, Inc. (CRNX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CRNX's current score at https://13fpro.ai/research/CRNX (free sign-up required for the full ranking).

Which hedge funds own the most CRNX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of CRNX include FMR, BlackRock,, FARALLON CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/CRNX as soon as new 13F filings post.

Where does 13F Pro source CRNX data?

All Crinetics Pharmaceuticals, Inc. fundamentals and ownership data come directly from SEC EDGAR. Crinetics Pharmaceuticals, Inc. files with the SEC under CIK 1658247. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CRNX in?

Crinetics Pharmaceuticals, Inc. (CRNX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CRNX research updated on 13F Pro?

CRNX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Crinetics Pharmaceuticals, Inc.(CRNX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1658247 CRNX stock profile & AI dashboard →

13F Pro Quality Score

26.5/100

Rank #2,502 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

93.8/100

Profitability

1.1/100

Balance Sheet

4.5/100

Earnings Quality

30.0/100

Free Cash Flow

1.0/100

Institutional Flow

91.6/100

Revenue Scale

4.0/100

Dilution Risk

0.1/100

CRNX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Crinetics Pharmaceuticals, Inc. (CRNX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CRNX at 26.5/100 on a 32-signal composite quality model, placing it at rank #2,502 of 2,879 stocks — the bottom half of the AI-ranked universe. CRNX scores in the top quartile across revenue growth (93.8), institutional flow (91.6). Areas of concern include free cash flow (1.0) and profitability (1.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Crinetics Pharmaceuticals, Inc. reports quarterly revenue of $10.7M, net income of $-127.8M, free cash flow of $-125.5M. Top institutional holders of CRNX by reported 13-F value include FMR, BlackRock,, FARALLON CAPITAL MANAGEMENT, based on the most recent SEC filings. CRNX trades on the Nasdaq exchange and files with the SEC under CIK 1658247. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CRNX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Crinetics Pharmaceuticals, Inc. directly from SEC EDGAR. Crinetics Pharmaceuticals, Inc.'s 13F Pro composite quality score has ranged between 6 and 41 since 2021, currently 26.5 — an improving long-term trajectory across 52 quarterly and live scoring snapshots.

✦

Fun facts about Crinetics Pharmaceuticals, Inc.

Quirks, history, and lore behind CRNX — the kind of stuff that makes a stock memorable.

1
The Basics
A clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in San Diego, California · focused on endocrine and rare diseases.
2
The Numbers
Still pre-revenue in the traditional sense, it burns cash to fund a pipeline of several candidates — a small-cap biotech with a market cap in the low billions.
3
The History
Founded in the 2010s, it was built around a singular scientific bet: that non-peptide, oral small molecules could do what injectable hormone analogues have done for decades, but better.
4
The Secret
Its entire pipeline targets the somatostatin receptor system — a niche so specific most pharma giants ignored it, which is exactly where this company planted its flag.
5
The Lore
Its lead program targets acromegaly — a rare condition caused by excess growth hormone — aiming to replace monthly injections with a daily pill.
6
The Giveaway
Ticker CRNX, a San Diego biotech whose drug paltusotine could make acromegaly patients trade the needle for a once-daily oral therapy.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$10.7M

Net Income

Q1 2026

$-127.8M

Free Cash Flow

Q1 2026

$-125.5M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+339.4% YoY

$4.7MFY 2022

FY19 $1.2MFY20 $71.0KFY21 $1.1MFY22 $4.7M

Net Income

-52.3% YoY

$-163.9MFY 2022

FY19 $-50.4MFY20 $-73.8MFY21 $-107.6MFY22 $-163.9M

Operating Income

-55.9% YoY

$-167.9MFY 2022

FY19 $-53.8MFY20 $-75.0MFY21 $-107.7MFY22 $-167.9M

EPS (Diluted)

-12.5% YoY

$-3.15FY 2022

FY19 —FY20 $-2.42FY21 $-2.80FY22 $-3.15

Total Assets

+0.3% YoY

$352.2MFY 2022

FY19 $130.4MFY20 $183.4MFY21 $351.0MFY22 $352.2M

Op. Cash Flow

-30.0% YoY

$-115.2MFY 2022

FY19 $-46.4MFY20 $-62.0MFY21 $-88.6MFY22 $-115.2M

Metric	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2016
Revenue	$4.7M +339.4%	$1.1M +1418.3%	$71.0K -94.0%	$1.2M -50.9%	$2.4M +312.2%	$589.0K
Net Income	$-163.9M -52.3%	$-107.6M -45.8%	$-73.8M -46.4%	$-50.4M -86.0%	$-27.1M -350.5%	$-6.0M
Operating Income	$-167.9M -55.9%	$-107.7M -43.7%	$-75.0M -39.2%	$-53.8M -87.5%	$-28.7M -375.0%	$-6.0M
EPS (Diluted)	$-3.15 -12.5%	$-2.80 -15.7%	$-2.42	—	—	—
Total Assets	$352.2M +0.3%	$351.0M +91.3%	$183.4M +40.7%	$130.4M -23.9%	$171.4M	—
Operating Cash Flow	$-115.2M -30.0%	$-88.6M -42.8%	$-62.0M -33.7%	$-46.4M -138.4%	$-19.5M -255.9%	$-5.5M

AI Insight: CRNX Financial Trends

Cash burn accelerating sharply as operating losses widened from -$83M in Q2 2024 to -$140M in Q1 2026, with no debt on balance sheet but equity erosion underway.

• Operating losses deepened from -$83M in Q2 2024 to -$140M in Q1 2026, a 69% increase over six quarters.

• Operating cash outflow surged from -$48M in Q2 2024 to -$125M in Q1 2026, the heaviest quarterly burn on record.

• Revenue showed first meaningful traction, rising from $0M to $11M in Q1 2026, suggesting early commercial or milestone activity.

• Equity rose to $1,281M in Q1 2026 from $992M in Q4 2025, indicating a likely capital raise offsetting ongoing losses.

⚠ Quarterly cash burn hit -$125M in Q1 2026; runway duration depends entirely on pace of future capital raises.

⚠ Revenue inflection from $0M to $11M warrants monitoring — needs sustained growth to meaningfully offset rising losses.

⚠ Equity declined from $1,325M in Q4 2024 to $992M in Q4 2025 before Q1 2026 raise; dilution risk remains elevated.

AI Insight: CRNX Ratio Trends

Capital efficiency deteriorating sharply: ROIC plunged from -28.6% in Q4 2024 to -53.9% in Q4 2025, signaling accelerating cash burn as CRNX scales operations.

• ROIC worsened from -28.6% in Q4 2024 to -53.9% in Q4 2025 — a 25.3pp deterioration over four quarters.

• ROA deepened from -22.5% in Q4 2024 to -43.6% in Q4 2025, reflecting asset base expansion outpacing returns.

• Q1 2026 shows partial sequential recovery: ROIC improved to -43.9% from -53.9% in Q4 2025, though still well below Q4 2024 levels.

⚠ ROIC at -43.9% in Q1 2026 remains far worse than -39.9% a year prior (Q2 2024), suggesting no structural improvement yet.

⚠ OpMargin and D/E data are entirely absent — investors lack visibility into cost structure and leverage trajectory.

⚠ Whether Q1 2026's sequential ROIC rebound (-53.9% to -43.9%) marks a true inflection or seasonal noise warrants close monitoring.

Get alerted when CRNX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Crinetics Pharmaceuticals, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CRNX

FMR LLC
$572.4M15,759,799 sh
BlackRock, Inc.
$308.0M8,478,815 sh
FARALLON CAPITAL MANAGEMENT LLC
$302.8M8,338,098 sh
WELLINGTON MANAGEMENT GROUP LLP
$296.3M8,157,204 sh
DRIEHAUS CAPITAL MANAGEMENT LLC
$232.3M6,395,922 sh
VANGUARD CAPITAL MANAGEMENT LLC
$169.8M4,673,935 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$168.5M4,638,511 sh
JANUS HENDERSON GROUP PLC
$164.2M4,520,251 sh
EcoR1 Capital, LLC
$155.7M4,288,120 sh
Bellevue Group AG
$119.1M3,280,000 sh

Fund	Value	Shares
FMR LLC	$572.4M	15,759,799
BlackRock, Inc.	$308.0M	8,478,815
FARALLON CAPITAL MANAGEMENT LLC	$302.8M	8,338,098
WELLINGTON MANAGEMENT GROUP LLP	$296.3M	8,157,204
DRIEHAUS CAPITAL MANAGEMENT LLC	$232.3M	6,395,922
VANGUARD CAPITAL MANAGEMENT LLC	$169.8M	4,673,935
VANGUARD PORTFOLIO MANAGEMENT LLC	$168.5M	4,638,511
JANUS HENDERSON GROUP PLC	$164.2M	4,520,251
EcoR1 Capital, LLC	$155.7M	4,288,120
Bellevue Group AG	$119.1M	3,280,000

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CRNX on your watchlist

Track score changes the day Crinetics Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CRNX a good stock to buy?

13F Pro's AI-powered analysis of Crinetics Pharmaceuticals, Inc. (CRNX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CRNX are available on the CRNX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CRNX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CRNX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Crinetics Pharmaceuticals, Inc.'s investment landscape.